Get the Stockscreener App
84.62
2.46%
2.03
After Hours:
72.10
-12.52
-14.80%
Rhythm Pharmaceuticals Inc stock is traded at $84.62, with a volume of 1.15M.
It is up +2.46% in the last 24 hours and down -14.65% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$82.59
Open:
$82.6
24h Volume:
1.15M
Relative Volume:
1.47
Market Cap:
$5.78B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-27.22
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
-1.44%
1M Performance:
-14.65%
6M Performance:
-14.65%
1Y Performance:
+59.93%
1-Day Range:
$80.99
$84.85
1-Week Range:
$80.70
$100.00
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
84.62 | 5.64B | 189.76M | -196.54M | -156.63M | -3.1087 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
Levels Update: What hedge funds are buying Rhythm Pharmaceuticals IncMarket Rally & Accurate Entry/Exit Alerts - baoquankhu1.vn
Rhythm wins US nod for Imcivree in rare hypothalamic obesity - The Pharma Letter
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - BioSpace
Tech Rally: Is Rhythm Pharmaceuticals Inc. gaining market share2026 PreEarnings & Technical Pattern Based Signals - baoquankhu1.vn
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setme - The National Law Review
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity - Yahoo Finance
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch - Yahoo Finance
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide - MarketBeat
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' - Investor's Business Daily
Rhythm Pharmaceuticals (RYTM) Receives Buy Rating and Raised Pri - GuruFocus
RYTM: Citigroup Raises Price Target on Rhythm Pharmaceuticals | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Expands IMCIVREE Distribution Part - GuruFocus
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide - Insider Monkey
RYTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap UpHere's What Happened - MarketBeat
FDA Approves IMCIVREE (Setmelanotide) as First Therapy for Acquired Hypothalamic Obesity in Adults and Children 4+ - Minichart
**Rhythm Pharmaceuticals Surges with Significant Market Moves After FDA Expansion** - StocksToTrade
Rhythm Pharmaceuticals jumps as investors focus on FDA decision timing for hypothalamic obesity label expansion - Quiver Quantitative
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA - TipRanks
Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy - TipRanks
Why Is Rhythm Pharma Stock Gaining Friday?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% placebo‑adjusted BMI - TradingView
Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN) - Benzinga
Rhythm Pharmaceuticals (Nasdaq: RYTM) gains FDA OK for IMCIVREE in acquired hypothalamic obesity - Stock Titan
Rhythm obesity drug wins broader use from FDA - BioPharma Dive
HC Wainwright Analysts Lower Earnings Estimates for RYTM - MarketBeat
After setback, Rhythm gets good news on Imcivree from FDA - pharmaphorum
Rhythm Pharmaceuticals (RYTM) Gains on FDA Approval for Expanded Use of Imcivree - GuruFocus
Rhythm Pharmaceuticals stock jumps on FDA approval - Investing.com
Rhythm Pharmaceuticals stock jumps on FDA approval By Investing.com - Investing.com Canada
After receiving approval from the U.S. Food and Drug Administration (FDA) for its brain injury-related obesity treatment, Rhythm Pharmaceuticals Inc. (RYTM) shares surged 7.4% in pre-market trading. - Bitget
Rhythm Pharma higher after FDA label expansion for lead drug - Seeking Alpha
Rhythm's therapy becomes first FDA-approved treatment for brain damage-related obesity - Reuters
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals - Indian Pharma Post
Is First FDA‑Approved IMCIVREE Use In Hypothalamic Obesity Altering The Investment Case For Rhythm Pharmaceuticals (RYTM)? - Sahm
5 Most Promising Stocks Under $100 to Buy - Insider Monkey
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - The Manila Times
Rhythm Awaits FDA Decision On Expanded Use Of Imcivree In Hypothalamic Obesity - RTTNews
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - MSN
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism - Insider Monkey
H.C. Wainwright cuts Rhythm Pharmaceuticals stock price target on trial miss - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) expected to beat earnings estimates: Should you buy? - MSN
HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating - TipRanks
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK) - The Globe and Mail
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
Mar 04 '26 |
Sale |
89.56 |
5,614 |
502,790 |
160 |
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):